25CN-NBOMe, also known as 2C-CN-NBOMe or NBOMe-2C-CN, is a derivative of the phenethylamine 2C-CN. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the serotonin 5-HT2A receptor.
Interactions
Pharmacology Pharmacodynamics + Target Affinity (Ki, nM) 5-HT1A 5-HT1B 5-HT1D 5-HT1E 5-HT1F 5-HT2A 1.8–4.6 (Ki)0.40–6.7 ()77–148% () 5-HT2B 21–47 (Ki)12 ()79% () 5-HT2C 8–180 (Ki)9.3–230 ()91–101% () 5-HT3 5-HT4 5-HT5A 5-HT6 145 5-HT7 α1A–α1D α2A–α2C β1–β3 D1–D5 H1–H4 M1–M5 I1 σ1, σ2 (Ki) () () (Ki) () () (Ki) () () Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs:
25CN-NBOMe acts as a potent and selective agonist of the serotonin 5-HT2A receptor. To a lesser extent, it also acts as an agonist of the serotonin 5-HT2B and 5-HT2C receptors.
History 25CN-NBOMe was first described in the scientific literature by 2010.
Society and culture Legal status Canada 25CN-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.
United Kingdom
See also 25-NB 2C-CN 25CN-NBOH
References
External links 25CN-NBOMe - Isomer Design The Small & Handy 25CN-NBOMe Thread - Bluelight